JW (Cayman) Therapeutics Co. Ltd (JWCTF)

Market Cap	101.51M -7.2%
Revenue (ttm)	40.55M +79.3%
Net Income	-79.39M
EPS	-0.19
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300
Average Volume	60,535
Open	0.3070
Previous Close	0.3150
Day's Range	0.3070 - 0.3070
52-Week Range	0.2500 - 0.6602
Beta	1.97
RSI	44.54
Earnings Date	Mar 26, 2026

About JWCTF

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 292
• Stock Exchange: OTCMKTS
• Ticker Symbol: JWCTF

Financial Performance

In 2025, JWCTF's revenue was 283.65 million, an increase of 79.28% compared to the previous year's 158.22 million. Losses were -555.29 million, -5.98% less than in 2024.

Financial numbers in CNY